Category Archives: Business of Biotech

| 10/25/2011

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

Stock Ticker

The latest IPO window has stalled. There have been five IPO withdrawals since June and around 30 since 2005. Global macro events are threatening to completely shut it. Reverse mergers have become an increasingly popular option with eight transactions in the last year. Unfortunately, 47 percent of reverse mergers have decreased in value post-close since 2008. At the 2011 BIO Investor Forum, a panel of experts examined the current financing environment and what private executive Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , , , ,
| 10/13/2011

Boosting Investment in Biotech

Biofuel Research

The President’s Council on Jobs and Competitiveness issued an interim report with suggestions to increase job creation and growth in the U.S., as well as plans for encouraging investment in the industry. Of particular interest to the biotech industry, the report offers suggestions for streamlining the FDA approval process. The report also outlines ideas for eliminating capital gains on investments of $25 million or less that are held for at least five years and recommends Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,
| 10/13/2011

BayBio Announces Lifetime Achievement DiNA Award Recipient

BayBio

Dr. Michael Hunkapiller has been named BayBio’s 2011 Lifetime Achievement DiNA Award recipient. He will be honored on Thursday, November 3rd, at the 2011 Pantheon Awards Ceremony, an annual program hosted by BayBio, a life science trade association representing the industry in Northern California. From the invention of the DNA sequencer during his days at Caltech, to the introduction of first automated DNA sequencer in 1986 and the realization of the Human Genome Mapping Project Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,